Filtros de búsqueda

Lista de obras de Peter Hillmen

A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia

scientific journal article

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relap

artículo científico publicado en 2014

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

artículo científico publicado en 2015

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

scientific article published on 01 May 2019

Advancing therapy for chronic lymphocytic leukemia--the role of rituximab

artículo científico publicado en 2004

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

artículo científico publicado en 2007

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial

artículo científico publicado en 2012

Alemtuzumab therapy in B-cell lymphoproliferative disorders

artículo científico publicado en 2003

Altered natural killer cell subset homeostasis and defective chemotactic responses in paroxysmal nocturnal hemoglobinuria

artículo científico publicado en 2013

Assessing minimal residual disease in chronic lymphocytic leukemia

scientific article published on January 2008

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial ⬇️

artículo científico

Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry

artículo científico publicado en 2014

Beyond detectable minimal residual disease in chronic lymphocytic leukemia

artículo científico publicado en 2006

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

artículo científico publicado en 2004

CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy

artículo científico publicado en 2006

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

artículo científico publicado en 2002

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials ⬇️

artículo científico publicado en 2017

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial ⬇️

artículo científico publicado en 2016

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

artículo científico

Chronic lymphocytic leukaemia—moving towards cure? ⬇️

artículo científico publicado el 2 de octubre de 2010

Clinical and diagnostic implications of monoclonal B-cell lymphocytosis

scientific article published on March 2010

Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, ⬇️

artículo científico publicado en 2017

Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients

artículo científico publicado en 2004

Diagnosis and management of paroxysmal nocturnal hemoglobinuria

artículo científico publicado en 2005

Diagnostic criteria for monoclonal B-cell lymphocytosis

artículo científico publicado en 2005

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia

artículo científico publicado en 2003

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

artículo científico publicado en 2010

Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria

artículo científico publicado en 2010

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria

artículo científico publicado en 2004

Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

scientific article published on 21 January 2020

Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment?

scientific article published on January 2010

Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation ⬇️

artículo científico publicado en 2016

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

artículo científico publicado en 2005

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

artículo científico publicado en 2018

Experiences in the design and implementation of phase II trials in CLL.

artículo científico publicado en 2011

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

artículo científico publicado en 2011

Future prospects for fludarabine-containing regimens in the treatment of hematological cancers

artículo científico publicado en 2004

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial ⬇️

artículo científico publicado en 2017

Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia

artículo científico publicado en 2018

Guidelines for the diagnosis and management of adult aplastic anaemia

artículo científico publicado en 2015

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

artículo científico publicado en 2008

Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL.

artículo científico publicado en 2016

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia ⬇️

artículo científico publicado en 2015

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

artículo científico publicado en 2016

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

artículo científico publicado en 2016

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

artículo científico publicado en 2014

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

artículo científico publicado en 2014

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

artículo científico publicado en 2017

Immune-mediated hemolytic anemia

artículo científico publicado en 2004

Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL.

artículo científico publicado en 2002

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

artículo científico publicado en 2017

Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion

artículo científico publicado en 2002

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

artículo científico publicado en 2019

Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria ⬇️

artículo científico publicado el 25 de abril de 2013

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

artículo científico publicado en 2004

Minimal residual disease and survival in chronic lymphocytic leukemia.

artículo científico publicado en 2005

Minimal residual disease assessment in chronic lymphocytic leukaemia

artículo científico publicado en 2007

Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?

artículo científico publicado en 2006

Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts

artículo científico publicado en 2002

Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia

artículo científico publicado en 2008

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

artículo científico publicado en 2007

Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: a deficiency of NK cells, but not an NK cell deficiency ⬇️

artículo científico publicado en 2015

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

artículo científico publicado en 2010

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

artículo científico publicado en 2015

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

artículo científico publicado en 2015

Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience

artículo científico publicado en 2007

Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab

artículo científico publicado en 2010

Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia

artículo científico publicado en 2005

Phase 1b Study of Tirabrutinib in Combination With Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

scientific article published on 10 March 2020

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

artículo científico publicado en 2019

Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia

artículo científico publicado en 2017

Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).

artículo científico publicado en 2003

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

artículo científico publicado en 2018

Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy

artículo científico publicado en 2005

Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria

artículo científico publicado en 2007

Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria

artículo científico publicado en 2007

Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib

artículo científico publicado en 2015

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study

artículo científico publicado en 2014

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial

artículo científico publicado en 2016

Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.

artículo científico publicado en 2005

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

artículo científico publicado en 2005

Targeted Therapy for Chronic Lymphocytic Leukemia: A Glimpse Into the Future ⬇️

artículo científico publicado el 19 de diciembre de 2011

The biological and clinical relationship between CD5+23+ monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia

artículo científico publicado en 2007

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease

artículo científico publicado en 2005

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

artículo científico publicado en 2006

The glycosylphosphatidylinositol anchor and paroxysmal nocturnal haemoglobinuria/aplasia model

artículo científico publicado en 2002

The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients

artículo científico publicado en 2009

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab

artículo científico publicado en 2009

The role of complement inhibition in PNH.

artículo científico publicado en 2008

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

artículo científico publicado en 2002

Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function

artículo científico publicado en 2012

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Scientific article published on 2 Dec 2016

Using the biology of chronic lymphocytic leukemia to choose treatment

artículo científico publicado en 2011

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

artículo científico publicado en 2020

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

artículo científico publicado en 2018

Which patients with paroxysmal nocturnal hemoglobinuria (PNH) should be treated with eculizumab? ASH evidence-based review 2008.

artículo científico publicado en 2008

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda